OncoMatch/Clinical Trials/NCT05979961
Phase III Trial of Concurrent Chemotherapy Alone in Patients With Low-risk Nasopharyngeal Carcinoma
Is NCT05979961 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies gemcitabine and cisplatin (Induction chemotherapy) for nasopharyngeal carcinoma.
Treatment: gemcitabine and cisplatin (Induction chemotherapy) — The purpose of this study is to compare concurrent chemoradiotherapy (CCRT) alone with induction chemotherapy (gemcitabine+cisplatin) plus CCRT in patients with low-risk locoregionally advanced nasopharyngeal carcinoma(NPC).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Cancer type
Head and Neck Squamous Cell Carcinoma
Biomarker criteria
Required: EBV plasma EB Virus DNA <4000 copies/ml (<4000 copies/ml)
pretreatment plasm EB Virus DNA<4000copies/ml
Disease stage
Required: Stage III, IVA
Excluded: Stage T4N2, ANYTN3
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: radiation therapy
Exception: except for non-melanomatous skin cancers outside intended RT treatment volume
History of previous RT (except for non-melanomatous skin cancers outside intended RT treatment volume)
Cannot have received: chemotherapy
Prior chemotherapy or surgery (except diagnostic) to primary tumor or nodes
Cannot have received: surgery
Exception: except diagnostic
Prior chemotherapy or surgery (except diagnostic) to primary tumor or nodes
Lab requirements
Blood counts
leucocyte count ≥ 4000/μL, hemoglobin ≥ 90g/L and platelet count ≥ 100000/μL
Kidney function
creatinine clearance ≥ 60 ml/min
Liver function
ALT, AST < 1.5×ULN concomitant with ALP < 2.5×ULN, and bilirubin < ULN
Adequate marrow: leucocyte count ≥ 4000/μL, hemoglobin ≥ 90g/L and platelet count ≥ 100000/μL. Normal liver function test: ALT, AST < 1.5×ULN concomitant with ALP < 2.5×ULN, and bilirubin < ULN. Adequate renal function: creatinine clearance ≥ 60 ml/min.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05979961 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Does this trial require EBV?
Yes, EBV plasma EB Virus DNA <4000 copies/ml is a required biomarker for enrollment.
What disease stage is eligible?
Stage III or IVA is required.
Is there an age limit?
Yes. Patients must be 70 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages